Now that China has seen that Celsion's ThermoDox with RF heat ablation doesn't work, they will now be jumping onboard with Delcath's Chemosat therapy. As reported, Asian countries have a very high incidence rate of liver cancer and currently have very few options in fighting this dreadful cancer.
Delcath had amazing phase III trial results with Chemosat and when reported, investors jumped onboard quickly. During ASCO conference a dermatologist from Germany made very negative comments and the shorts decided to decimate the share price which they did, taking it from $16/share down to $2/share. This was so unfair to investors at the time. Now the time has come for Delcath to finally get their just rewards because unlike Celsion, their system really works and works extremely well.
FDA approval is set for June, 2013 and it is pretty well certain that they will get it. Delcath already has achieved the CE mark in Europe so this will be the last hurdle for them. When China finally gives their approval, this stock will go into orbit.
We all had plenty of time to sell (from April 20 until June 8, 2010) at $10+ per share. I only sold 50% of my shares and still have the Kool-aid stains on my shirt. Same scenario, since many of us got in way under $2. I do not blame any German dermatologists or anyone else. Buy low/sell to soon.